Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms
Executive Summary
As industry weighs the potential impact of FDA's guidance on good reprint practices, stakeholders are suggesting alternate policy approaches that could give companies sufficient clarity on how to conduct off-label dissemination
You may also be interested in...
False Claims Act Suits May Become Harder After Supreme Court Ruling
A U.S. Supreme Court ruling restricts when whistleblowers can sue someone for fraud against the government. But the opinion is limited to certain situations and may not affect suits brought against drug companies
False Claims Act Suits May Become Harder After Supreme Court Ruling
A U.S. Supreme Court ruling restricts when whistleblowers can sue someone for fraud against the government. But the opinion is limited to certain situations and may not affect suits brought against drug companies
FDA’s Off-Label Reprint Guidance Is Unlikely To Clarify Anything Very Soon
Companies hoping that the end of the comment period for FDA's draft guidance on "good reprint practices" will swiftly produce a final roadmap should probably not hold their breath